BioStem Technologies
biostemtechnologies.comNewsletter Sponsored
The Street Sheet
70,000 subscribers
Sponsorship Date
February 5, 2026
Sponsored 26 days ago
Industry
MedTech
Email Newsletter
About
No description available.
Ad Copy Example
FROM QUIET COMPOUNDER TO 2026 BREAKOUT? BioStem Technologies (OTCQB: BSEM) is emerging as one of the most compelling small-cap MedTech companies as 2026 begins. The company just completed the acquisition of BioTissue Holdings’ surgical and wound care business, instantly expanding its footprint into hospital-based, acute, and surgical wound care. Zacks Small Cap Research has assigned BSEM a $25.50 price target, highlighting confidence in the company’s profitable growth, clinical validation, and expanding market presence. For context, the stock closed at less than $7 today. Discover why BSEM is setting the standard for profitable, clinically proven MedTech growth in 2026. LEARN MORE
Preview Mode
This is limited preview data. Sign up to access contact information, email addresses, decision makers, and thousands more sponsors with advanced filtering.
Latest Active Sponsors
Unlock Complete Sponsor Data
This preview shows limited information. Get full access to contact details, decision maker names, email addresses, and advanced filtering across our database of thousands of active sponsors.